Skip links



  • 香港大学内外全科医学士
  • 皇家放射科医学院院士
  • 香港放射科医学院院士
  • 香港医学专科学院院士(放射科)
  • 香港大学李嘉诚医学院临床肿瘤学系荣誉临床助理教授




今天是情人节,不少暖男绞尽脑汁为女伴构思别出心裁的礼物。常言道,健康是上天赐给我们最大的礼物,不知各位男士又有 [...]


行医多年,见尽病人在抗癌路上的各种心态。有年轻患者确诊时本应有药可医,却因为各种原因放弃治疗,到最后撒手尘寰; [...]


肺癌是本港头号癌症杀手,可怕之处在于初期病征不明显,患者误以为普通「伤风咳」或吸烟引致气管不适,以致过半数确诊 [...]


1. Prognostic factors for oligometastasis after 1st line first or second generation TKI for EGFR-mutated metastatic NSCLC, ASCO 2017 Abstract e20521

2. Factors correlating with shorter survival after treatment: Aiding oncologists to choose who (not) to receive palliative systemic therapy. ASCO 2017 Abstract e21654

3. The real-world use of regorafenib for metastatic colorectal cancer: multicenter analysis of treatment pattern and outcomes in Hong Kong. BMJ 2016

4. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-Small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy. American Journal of Clinical Oncology 2016;29(4):355-362

5. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib. BMC Cancer 2016;16:147

6. Treatment outcomes of patients with early-stage lung cancer or pulmonary oligometastases treated with stereotactic body radiation therapy. ASM HKCR 2015

7. Discordant RAS status between primary and metastatic colorectal cancer and predicted pattern of metastases. Annals of Oncology 2015

8. Maintenance therapy with angiogenesis inhibitors in patient with stage IV CA lung. MIMS HK June 2015

9. Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer JTO?Volume 8, Issue 9, September 2013, 1148-1155

10. Pineal Parenchymal Tumor of Intermediate Differentiation: two cases treated with adjuvant radiotherapy. HKICC 2013

11. Predictors of treatment outcome in patients treated with radical chemoradiotherapy for stage III non-small cell lung cancer. ASM HKCR 2012

12. Safety and efficacy of cetuximab-XELOX combination in the first-line treatment of Kras wild-type metastatic colorectal cancer-QMH experience. ASM HKCR 2012

13. Comparative analysis of sequence of chemotherapy and targeted therapy for non-small cell lung cancer. ROAF 2010

14. Dosimetric analysis of pre-operative and post-operative concurrent chemotherapy with conformal radiotherapy delivered by 5 or 6 beams for rectal cancer. RCR-HKCR 2009 Joint Scientific Meeting & 17th ASM HKCR

15. Toxicity Profile and Efficacy of Oral Capecitabine as Adjuvant Chemotherapy for Chinese Patients with Stage III Colon Cancer. Dis Colon Rectum 2007; 50: 2180–2187

16. Twenty years experience in management of adenocarcinoma of uterine corpus. Poster presentation, ASM 2007

17. emedicine: nasopharynx, squamous cell carcinoma. Feb 2, 2007.

18. Health-related quality-of-life study in patients with carcinoma of the thyroid after thyroxine withdrawal for whole body scanning. Laryngoscope 116: 2060-2066 November 2006.

19. Factors affecting endogenous TSH rise after thyroxine withdrawal in preparation for I-131 whole body scanning: A prospective study of 142 patients with differentiated thyroid carcinoma.

20. Chemotherapy FOLFOX4 in inoperable metastatic colorectal cancer: QEH experience. 11th AOCR 2006 Hong Kong

21. Updated survival analysis of combined surgery and radiotherapy for major salivary gland carcinoma in department of clinical oncology, Queen Elizabeth Hospital. 11th ASM of HK Cancer Institute: Head & Neck & Chest Conference 2006

22. A comparative study of 105 lymphoepithelioma-like carcinoma & other common types of carcinoma of salivary glands (Poster presentation on 6th International conference on Head and Neck Cancer, Washington DC, USA November 2004

23. Definitive Radiotherapy for carcinoma of cervix: Retrospective analysis of prognostic factors concerning patient characteristics and treatment parameters in a local hospital in Hong Kong. May 2003 (unpublished)

24. Treatment outcome of platinum-based combination chemotherapy for advanced NPC – the experience of QEH

25. Radiotherapy for major salivary gland carcinoma: a single institution experience. HKICC 2000

26. Inverted papilloma – presentation of three cases and implication for treatment. Radiology 2000

27. Platinum-based combination chemotherapy for advanced carcinoma of the nasopharynx – The QEH experience. HKICC 1999



TypePhaseStudy title
BreastI/IIA Phase I/II, Open-label Study of Neratinib (HKI-272) in Combination With Capecitabine in Subjects With Solid Tumors and ErbB-1 Positive Metastatic or Locally Advanced Breast Cancer
BreastIIA Phase II Randomized, Open-label Study of Neratinib Versus Lapatinib Plus Capecitabine for the Treatment of ErbB-2-Positive Locally Advanced or Metastatic Breast Cancer
BrainIIIA randomized, double blind, placebo controlled, multicenter Phase III trial of bevacizumab, temozolomide and radiotherapy, followed by bevacizumab and temozolomide versus placebo, temozolomide and radiotherapy followed by placebo and temozolomide in patients with newly diagnosed glioblastoma
BrainIICilengitide for subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter- a mulitcenter, open-label, controlled Phase II study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone
LungIIIRandomized, multicenter, double-blind, phase III trial comparing the efficacy of Ipilimumab plus etoposide/platinum versus etoposide/platinum in subjects with newly diagnosed extensive-stage disease small cell lung cancer (ED-SCLC)
LungIIbA randomised, open-label Phase Iib trial of afatinib versus gefitinib as first-line treatment of patients with EGFR mutation positive advanced adenocarcinoma of the lung
LungIIIA Randomized, Phase III, Multicenter, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination with Tarceva? (Erlotinib) in Patients with Met Diagnostic-positive Non-small Cell Lung Cancer (NSCLC) who have Received Standard Chemotherapy for Advanced or Metastatic Disease
LungIIIPhase III, Randomized, Open-label Study of the Efficacy and Safety of Crizotinib versus Pemetrexed/Cisplatin or Pemetrexed/Carboplatin in Previously Untreated East Asian Patients with Non-squamous Carcinoma of the Lung Harboring a Translocation or Inversion Event involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus
LungIIIRandomized controlled trial of S-1 versus docetaxel in patients with non-small cell lung cancer who have received a platinum-based treatment
LungIIA multicenter, open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutations who have progressed on prior EGFR TKI treatment
LungIIA phase II, multicenter, single-arm study of oral LDK378 in crizotinib na?ve adult patients with ALK-activated non-small cell lung cancer
LungIIIBAn open label, multicentre, single-arm trial to access the safety of afatinib for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s)
LungIIA Multicenter, Open-Label Phase II Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung
LungIIIA phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib
LungIIIA Randomized, Double-blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 215 Compared with Bevacizumab in Subjects with Advanced Non-Small Cell Lung Cancer
LungIIIA Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab in Combination with Erlotinib as First-Line Treatment for Patients with MET-Positive Unresectable Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation
LungIIA Phase II, Multicentre, Single-arm Study Of MPDL3280A In Patients with PD-L1-Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
LungIIA Phase II, Multicenter, Single-arm Study of Oral AP26113 in Patients with ALK-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated with Crizotinib
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase-Positive Advanced Non Small Cell Lung Cancer Patients Previously Treated With Platinum-Based Chemotherapy and Crizotinib
A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (mCRC)
A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma
A Phase II, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC)
LungNAA multi-center retrospective observational study to evaluate PD-L1 Protein expression in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
LungIIA Phase II, Multicenter, Single-arm Study of Oral LDK378 in Crizotinib na?ve Adult Patients With ALK-activated Non-small Cell Lung Cancer
LungIVAn open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib
GastricIIIA Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects With Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
NPCIINivolumab as treatment for recurrent/metastatic nasopharyngeal carcinoma after failing two lines or more previous chemotherapy
Return to top of page